Note: Price/availability/specifications subject to change without notice. If not specified, all products and services are for in vitro research use only. Not for use in or on humans or animals.
Order offline: Phone: 1-617-401-8149, Fax: 1-617-606-5019, Email: message@sydlabs.com, or leave a message with a formal purchase order (PO) or credit card.

Features:

BP000028-GD2: Recombinant Human Long R3-IGF-­I

Source: E. coli ­derived.
The IGF-1 activity is calculated by the dose-dependant proliferation of murine BALBC 3T3 cells. The ED50 for this effect is less than 1 ng/ml, corresponding to a specific activity of 1.0×10^6 IU/mg.
Purity > 95%, by SDS­-PAGE and RP-HPLC.

BP000216-CYT-022: Recombinant Human Long R3-IGF-­I

Source: E. coli derived.
The ED50 as determined by the stimulation of protein synthesis in L6 myoblasts is less then 10 ng/ml, corresponding to a specific activity of 100,000 units/mg.
Purity > 95%, by SDS-PAGE.

Description:

Background
Human Long-[Arg3]insulin-like growth factor-I (IGF-I) is an 83 amino acid analog of insulin-like growth factor-I that has been modified by a Glu3→Arg mutation and a 13-amino acid extension appended to the N terminus. Human Long-R3-IGF-I is significantly more potent than human IGF-I in vitro. The enhanced potency is due to the markedly decreased binding of human Long-R3-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs(1).

References:

1. Francis. et al. 1992 Novel recombinant fusion protein analogues of insulinlike growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol 8: 213–223.

BP000028-GD2: Recombinant Human Long R3-IGF-­I

Source: E. coli ­derived
N-terminal sequence analysis: Met-Phe-Pro-Ala-Met
Predicted molecular mass: 9.1 kDa
The IGF-1 activity is calculated by the dose-dependant proliferation of murine BALBC 3T3 cells. The ED50 for this effect is less than 1 ng/ml, corresponding to a specific activity of 1.0×10^6 IU/mg.
Endotoxin Level: < 0.025 EU per 1 μg of the protein by the LAL method.
Purity > 95%, by SDS­-PAGE and RP-HPLC.
Formulation: Lyophilized from 20 mM PB, 4.5% Mannitol, pH 7.2. Steri-filtered before lyophilization.
Reconstitution: 1 ml ddH2O for 1 mg protein to final concentration of 1 mg/ml.

BP000216-CYT-022: Recombinant Human Long R3-IGF-­I

Source: E. coli derived.
Predicted molecular mass: 9.1 kDa.
The ED50 as determined by the stimulation of protein synthesis in L6 myoblasts is less then 10 ng/ml, corresponding to a specific activity of 100,000 units/mg.
Purity > 95%, by SDS-PAGE.
Formulation: Lyophilized from a 0.2 µm filtered concentrated solution in 1xPBS.
Reconstitution: It is recommended to reconstitute the lyophilized Long R3 IGF1 in sterile ddH2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.

Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-­thaw cycles.
12 months from date of receipt, -20 to -­70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution.

Related Links:

• IGF-1 Protein (II)
• IGF-1 Protein (III)
• IGF-1 Antibody
• IGF-1 ELISA Kit
• IGF-1R (Phosphorylated) Antibody (I)